Clinical Efficacy on Erchentang Combined with Sanzi Yangqintang in Treatment of Cough Variant Asthma in Children with Phlegm Evil Accumulation Lung Syndrome
10.13422/j.cnki.syfjx.20210624
- VernacularTitle:二陈汤合三子养亲汤加减治疗痰邪蕴肺型儿童咳嗽变异性哮喘的临床观察
- Author:
Jun WAN
1
;
Zhou YU
1
;
Meng-tian SUN
1
;
Xiang-zheng YANG
1
Author Information
1. Shenzhen Hospital of Beijing University of Chinese Medicine（Longgang），Shenzhen 518100，China
- Publication Type:Research Article
- Keywords:
cough variant asthma;
children;
phlegm evil accumulation lung;
Erchentang;
Sanzi Yangqintang;
airway inflammation;
airway hyperresponsiveness
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2021;27(10):58-63
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the clinical efficacy of Erchentang combined with Sanzi Yangqintang in the treatment of cough variant asthma （CVA） in children with phlegm-evil accumulation lung syndrome and its influence on airway inflammation and airway hyperresponsiveness （AHR）. Method:A total of one hundred and sixteen children were randomly divided into observation group and control group 58 cases in each group. Patients in both groups took montelukast sodium chewable tablets orally， 5 mg/time， once daily， at night before bedtime. In observation group， patients took Erchentang and Sanzi Yangqintang modified granules orally. While patients in control group took Erchentang and Sanzi Yangqintang placebo granules orally. Treatment course continued six weeks for two groups. Before and after treatment， the cough symptom scores and phlegm evil accumulating lung syndrome scores were recorded every week. The cough remission time and cough disappearance time were recorded， followed up for 24 weeks to record cough recurrence. Leicester Cough quality of life questionnaire （LCQ） was scored before and after treatment. The ratio of induced sputum eosinophils （EOS） and the levels of interleukin-4 （IL-4）， IL-5， IL-12， IL-13 were measured before and after treatment. The cumulative doses of exhaled nitric oxide （FeNO） and methacholine （PD20） were measued before and after therapy. Safety evaluation was conducted. Result:The scores of cough symptom and phlegm-evil accumulation lung syndrome at different time points were decreased gradually in two groups of children after treatment （Fcontrol group=5.277， Fobservation group=7.636，P<0.01）. The scores of cough symptom and phlegm-evil accumulation in the lung syndrome of observation group were lower than those in control group （P<0.01） at the same period. The durations of cough relief and cough disappearance in observation group were shorter than those in control group （P<0.01）. Within 24 weeks of follow-up， the recurrence rate of children in observation group was 68.97% （40/58）， lower than 84.48% （49/58） in control group （χ2=3.917，P<0.05）. Children in observation group had fewer relapses than those in control group （P<0.01）. The total LCQ scores and scores of all dimensions in observation group were higher than those in control group （P<0.01）. The EOS， IL-4， IL-5 and IL-13 levels in observation group were lower than the data in control group， and IL-12 level was higher than that in control group （P<0.01）. FeNO of children in observation group was lower than that in control group （P<0.01）， while PD20 was more than that of control group （P<0.01）. The total effective rate of clinical curative effect of children in observation group was 96.55% （56/58）， which was higher than 82.76% （48/58） in control group （χ2=5.948，P<0.05）. Conclusion:Erchentang combined with Sanzi Yangqintang for children with CVA phlegm evil accumulation lung syndrome can further control the symptoms of cough， shorten the course of cough， improve the quality of life， and reduce airway inflammation and AHR， reduce the recurrence rate. The clinical efficacy is better than using montelukast only， and it is safe and has good clinical value.
